NeuroSense Therapeutics Ltd. NRSNW
Nov 5, 2026, 1:51 PM EST
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 318.20K
- EPS (ttm)
- -0.935
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 10.01K
- Open
- 0.30
- Previous close
- 0.0129
- Day's range
- 0.0099 – 0.013
- 52-week range
- 0.0099 – 0.013
- Beta
- 1.56
1D -0.0076 (-58.91%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -6.63M
- Total cash
- 1.21M
- Total debt
- 36.00K
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Next earnings
Consensus EPS estimate 0.00.
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- neurosense-tx.com
News
NeuroSense Therapeutics Files U.S. Patent Application Covering Methods Of Treating Traumatic Brain Injury And Related Central Nervous System Injuries With Combination Of Ciprofloxacin And Celecoxib - NeuroSense Therapeutics Announces Nasdaq Hearings Panel Date Of November 10; Minimum Bid Price Compliance Already Regained; Sees PrimeC Milestones In December And Q1 2027
NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Short Interest Down 15.5% in December
Your note
Sign in to keep a note on NRSNW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Clear Street LLC | 3.56% | 65,759 | 29.59K | Sep 29, 2024 |
| Citadel Advisors Llc | 1.37% | 25,274 | 11.37K | Sep 29, 2024 |
| Warberg Asset Management LLC | 1.09% | 20,201 | 9.09K | Sep 29, 2024 |
| UBS Group AG | 0.01% | 200 | 89 | Sep 29, 2024 |